Monopar's ALXN1840 Phase 2 Data Shows Significant Liver Stabilization, Neurologic Gains in Wilson Disease
MNPR has more than doubled off its 52-week low of $28.4.
Summary
Monopar Therapeutics presented detailed positive Phase 2 data for its lead candidate, ALXN1840, in treatment-experienced Wilson disease patients at the EASL 2026 conference. The results demonstrated significant liver disease stabilization, with 67% of patients showing fibrosis stage improvement or stabilization, alongside statistically significant improvements in neurologic symptoms and quality of life. This presentation follows the peer-reviewed publication of this Phase 2 data, which was announced via an 8-K on May 19th, and builds on the highly positive Phase 3 data for ALXN1840 announced on April 19th. These detailed positive outcomes further de-risk ALXN1840 and strengthen its clinical profile as the company targets an NDA submission by mid-2026.
At the time of this announcement, MNPR was trading at $65.04 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $435.7M. The 52-week trading range was $28.40 to $105.00. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.